CRMD logo

CRMD
CorMedix Inc

23,442
Mkt Cap
$578.31M
Volume
1.78M
52W High
$17.43
52W Low
$5.60
PE Ratio
3.58
CRMD Fundamentals
Price
$7.34
Prev Close
$7.36
Open
$7.38
50D MA
$9.49
Beta
1.09
Avg. Volume
4.19M
EPS (Annual)
-$0.3046
P/B
1.54
Rev/Employee
$668,802.61
$425.69
Loading...
Loading...
News
all
press releases
CorMedix's (CRMD) Buy Rating Reaffirmed at D. Boral Capital
D. Boral Capital reaffirmed a "buy" rating and set a $14.00 price target on shares of CorMedix in a research note on Wednesday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside
CRMD heads into Q4 earnings with DefenCath driving revenues, boosted by strong outpatient dialysis use and added contributions from acquired Melinta products.
Zacks·3d ago
News Placeholder
Analyst Expectations For Cormedix's Future
read more...
Benzinga·3d ago
News Placeholder
CorMedix Investor Day: Melinta Deal Fuels Shift to Multi-Product Pharma, Rezzayo Q2 Data Ahead
CorMedix (NASDAQ:CRMD) used its 2026 Analyst and Investor Day to outline its shift from a single-product renal-focused company to what management described as a diversified, cash-flow-generating...
MarketBeat·4d ago
News Placeholder
130,244 Shares in CorMedix Inc $CRMD Purchased by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd purchased a new stake in CorMedix Inc (NASDAQ:CRMD - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission...
MarketBeat·14d ago
News Placeholder
CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?
CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.
Zacks·15d ago
News Placeholder
CorMedix (NASDAQ:CRMD) Trading Up 6% - Here's What Happened
CorMedix (NASDAQ:CRMD) Trading 6% Higher - Still a Buy...
MarketBeat·19d ago
News Placeholder
CorMedix Inc (NASDAQ:CRMD) Given Consensus Rating of "Buy" by Brokerages
CorMedix Inc (NASDAQ:CRMD - Get Free Report) has earned an average rating of "Buy" from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two investment...
MarketBeat·19d ago
News Placeholder
Research Analysts Set Expectations for CorMedix Q1 Earnings
CorMedix Inc (NASDAQ:CRMD - Free Report) - HC Wainwright issued their Q1 2026 earnings per share estimates for CorMedix in a research note issued on Friday, January 23rd. HC Wainwright analyst B...
MarketBeat·19d ago
News Placeholder
Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?
CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption.
Zacks·22d ago
<
1
2
...
>

Latest CRMD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.